Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.


Regulatory News:



Novo Nordisk A/S and BIOCORP Production SA (Paris:ALCOR) announced today that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which

Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that new data will be presented

RUBIS: Information relating to the total number of voting rights and shares as of 31/05/2023
RUBIS: Information relating to the total number of voting rights and shares as of 31/05/2023
RUBIS: Information relating to the total number of voting rights and shares as of 31/05/2023
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 20, 2023: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 20, 2023


Regulatory News:



The shareholders of Median Technologies (ALMDT:PA) (Paris:ALMDT) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on

RUBIS: Results from the capital increase reserved for Group employees
RUBIS: Results from the capital increase reserved for Group employees
RUBIS: Results from the capital increase reserved for Group employees
Voyageurs du Monde: Cyber attack - additional information
Voyageurs du Monde: Cyber attack - additional information
Voyageurs du Monde: Cyber attack - additional information
Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the

Pernod Ricard: Wild Spirit for Wild Spirits: Nocheluna Sotol Embarks on Redefining the Mexican Spirits Category for Europe: https://mms.businesswire.com/media/20200212005993/en/773259/5/Createurs_de_Convivialite.jpg
Pernod Ricard: Wild Spirit for Wild Spirits: Nocheluna Sotol Embarks on Redefining the Mexican Spirits Category for Europe


Regulatory News:



Press Release – Paris, 25 May 2023



Pernod Ricard (Paris:RI):



After a successful launch in Mexico City and New York in 2022, Nocheluna Sotol made its European debut last

Orby Elevate Selects EUTELSAT 117 West A For DTH TV Distribution Across the US: https://mms.businesswire.com/media/20191112005524/en/397236/5/Eutelsat_Communications_logo.jpg
Orby Elevate Selects EUTELSAT 117 West A For DTH TV Distribution Across the US


Regulatory News:



Eutelsat Communications (Euronext Paris: ETL) announces that Orby Elevate has selected the EUTELSAT 117 West A satellite for the distribution of its first major mainstream

Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq

Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces today the results of

Voyageurs du Monde: Full recovery of activity at Voyageurs du Monde
Voyageurs du Monde: Full recovery of activity at Voyageurs du Monde
Voyageurs du Monde: Full recovery of activity at Voyageurs du Monde
Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes


Pflichtmitteilung:



Valbiotis (FR0013254851 – ALVAL, PEA/PME-fähig) (Paris:ALVAL), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen

Opening of conciliation proceedings
Opening of conciliation proceedings
Opening of conciliation proceedings
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes


Regulatory News:



Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and

Voyageurs du Monde: Cyber attack contained at Voyageurs du Monde
Voyageurs du Monde: Cyber attack contained at Voyageurs du Monde
Voyageurs du Monde: Cyber attack contained at Voyageurs du Monde
Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

UK Atomic Energy Authority to Develop Fusion Energy Plant with Dassault Systèmes’ 3DEXPERIENCE Platform: https://mms.businesswire.com/media/20191104005004/en/734381/5/3DS_Corp_Logotype_Blue_RGB.jpg
UK Atomic Energy Authority to Develop Fusion Energy Plant with Dassault Systèmes’ 3DEXPERIENCE Platform


Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced that its 3DEXPERIENCE platform was selected for UKAEA’s Spherical Tokamak for Energy Production (STEP) program, which aims

Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

EQS-News: Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
EQS-News: Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
EQS-News: Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
ALD: Trading update on Q1 2023 results
ALD: Trading update on Q1 2023 results
ALD: Trading update on Q1 2023 results
IC.IDO Weave der ESI Group beschleunigt die Produktentwicklung und die Entscheidungsfindung in Unternehmen im industriellen Metaverse: https://mms.businesswire.com/media/20210510005423/de/877137/5/2020_11_04_MKTG_ESI_Logo_ColorTagline_rgb.jpg
IC.IDO Weave der ESI Group beschleunigt die Produktentwicklung und die Entscheidungsfindung in Unternehmen im industriellen Metaverse


ESI Group (ISIN Code: FR0004110310, Symbol: ESI), ein führender Anbieter von Simulations- und Virtual Prototyping-Software für Branchen weltweit, hat die Einführung von IC.IDO Weave bekannt

ESI Group’s IC.IDO Weave Accelerates Product Development and Enterprise Decision-making in the Industrial Metaverse: https://mms.businesswire.com/media/20210510005423/de/877137/5/2020_11_04_MKTG_ESI_Logo_ColorTagline_rgb.jpg
ESI Group’s IC.IDO Weave Accelerates Product Development and Enterprise Decision-making in the Industrial Metaverse


Regulatory News:



ESI Group (ISIN Code: FR0004110310, Symbol: ESI), a leading simulation and virtual prototyping software provider for industries worldwide, has announced the launch of IC.IDO